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Abstract
AIM: To determine if subclinical abnormal glucose tol-
erance (SAGT) has influence on survival of non-diabetic 
patients with liver cirrhosis.
METHODS: In total, 100 patients with compensated 
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liver cirrhosis and normal fasting plasma glucose were 
included. Fasting plasma insulin (FPI) levels were mea-
sured, and oral glucose tolerance test (OGTT) was 
performed. According to OGTT results two groups of 
patients were formed: those with normal glucose toler-
ance (NGT) and those with SAGT. Patients were fol-
lowed every three months. The mean follow-up was 
932 d (range of 180-1925). Survival was analyzed by 
the Kaplan-Meyer method, and predictive factors of 
death were analyzed using the Cox proportional hazard 
regression model.
RESULTS: Of the included patients, 30 showed NGT and 
70 SAGT. Groups were significantly different only in age, 
INR, FPI and HOMA2-IR. Patients with SAGT showed 
lower 5-year cumulated survival than NGT patients 
(31.7% vs  71.6%, P  = 0.02). Differences in survival 
were significant only after 3 years of follow-up. SAGT, 
Child-Pugh B, and high Child-Pugh and Model for End-
Stage Liver Disease (MELD) scores were independent 
predictors of death. The causes of death in 90.3% of 
cases were due to complications related to liver disease. 
CONCLUSION: SAGT was associated with lower sur-
vival. SAGT, Child-Pugh B, and high Child-Pugh and 
MELD scores were independent negative predictors of 
survival. 
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: In this controlled prospective long term study 
we demonstrated that subclinical forms of abnormal 
glucose tolerance (IGT) or diabetes mellitus (DM) may 
influence survival of non-diabetic cirrhotic patients. Pre-
viously it had been demonstrated that clinically overt 
MATERIALS AND METHODS
Patients
Patients with LC, who were seen in our hospital from Au-
gust 2007 to August 2012, were prospectively evaluated. 
Only those with normal FPG (< 100 mg/dL), no history 
of  overt DM, with clinical or histological diagnosis of  
LC, aged over 18 years old and without clinically evident 
complications of  liver disease (e.g., esophageal or gastric 
variceal bleeding, hepatic encephalopathy, hepatorenal 
syndrome, infection, spontaneous bacterial peritonitis, 
and moderate to severe ascites), were selected for the 
study (patients with complications were excluded in order 
to avoid the effect of  medications used for treating them, 
on glucose metabolism of  patients). Clinical diagnosis of  
LC was made by using a combination of  clinical symp-
toms, laboratory tests and imaging studies (abdominal 
ultrasonography or CT scan)[21,22]. The etiology of  cirrho-
sis was determined as follows: Alcohol-related cirrhosis 
was determined when daily alcohol consumption was > 
80 g in men and > 40 g in women for at least 10 years 
with negative viral, metabolic and autoimmune markers. 
Diagnosis of  hepatitis C virus and B virus related cir-
rhosis was determined with specific viral markers (HBsAg 
or anti-HCV). Autoimmune liver disease was diagnosed 
with specific autoimmune markers (anti-nuclear antibod-
ies, anti-smooth muscle antibodies or liver-kidney anti-
microsomal antibodies). Meanwhile, cryptogenic cirrhosis 
was established in the absence of  any of  the causes above 
described[23].
Informed consent was obtained from each patient. 
The protocol was approved by The Research and Ethics 
Committee of  the Faculty of  Medicine of  the Autono-
mous University of  Nuevo Leon in Monterrey.
Fasting plasma insulin and OGTT
Fasting plasma insulin (FPI) levels were measured and 
OGTT was performed according to the World Health 
Organization criteria[24]. Patients were fasted for at least 
12 h, and baseline plasma glucose was measured; then, 
they were given an oral glucose load (75 g). Additionally, 
plasma glucose (PG) levels were measured every 30 min 
for 2 h. The results were interpreted as follows: a) normal 
glucose tolerance (NGT) if  2-h PG was < 140 mg/dL; 
IGT if  2-h PG between 140 mg/dL and 200 mg/dL; 
and DM if  2-h PG > 200 mg/dL. Plasma HbA1c was 
not used for diagnosing DM due to its low sensitivity re-
ported in cirrhotic patients[19].
FPI was measured using the electrochemilumines-
cence method (normal values: 5-20 μU/mL). HOMA2-
IR index (Homeostasis Model Assessment 2-Insulin Re-
sistance Index) was calculated using the following online 
software (http://www.dtu.ox.ac.uk/homacalculator/in-
dex.php). 
Assessments 
The following data were recorded in a database specially 
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DM is associated with low survival of cirrhotic patients. 
This issue is important since a high proportion of cir-
rhotic patients (about 70%) without history of DM and 
with normal fasting plasma glucose have subclinical 
abnormal glucose tolerance. The use of oral glucose 
tolerance test for early recognition and treatment of 
DM may improve prognosis of these patients. 
García-Compeán D, Jáquez- Quintana JO, Lavalle-González FJ, 
González-González JA, Muñoz-Espinosa LE, Villarreal-Pérez JZ, 
Maldonado-Garza HJ. Subclinical abnormal glucose tolerance 
is a predictor of death in liver cirrhosis. World J Gastroenterol 
2014; 20(22): 7011-7018  Available from: URL: http://www.
wjgnet.com/1007-9327/full/v20/i22/7011.htm  DOI: http://dx.doi.
org/10.3748/wjg.v20.i22.7011
INTRODUCTION
Overt diabetes mellitus (DM) has been reported in 
21%-30% of  patients with liver cirrhosis (LC)[1]. DM may 
arise from a progressive disorder of  insulin secretion in 
the presence of  liver and muscle resistance to insulin[2,3].
DM is related to LC in two ways: (1) type 2 DM (T2DM) 
(often associated with metabolic syndrome) causes nonal-
coholic fatty liver disease (steatosis, steatohepatitis, LC, and 
hepatocellular carcinoma)[4-7]; and (2) DM may develop as 
a complication of  LC, which is known as “hepatogenous 
diabetes” (HD)[8,9]. As liver disease advances, DM becomes 
clinically evident[10,11]. T2DM and HD are associated with 
an increased risk of  complications of  chronic liver diseases 
and mortality[7,9,12-17]. 
On the other hand, subclinical abnormal glucose 
tolerance (SAGT) disorders, such as impaired glucose tol-
erance or DM (called subclinical since they are detected 
only by means of  an oral glucose tolerance test), may be 
observed in 45% and 22%, respectively, of  patients with 
LC and no history of  DM[18,19]. Therefore, the prevalence 
of  DM and impaired glucose tolerance (IGT) may be 
underestimated when only fasting plasma glucose (FPG) 
levels are taken into account. Our group has recently 
published a study determining the prevalence of  T2DM, 
DH and IGT in patients with LC who underwent oral 
glucose tolerance test (OGTT). In total, 86% of  the cases 
had either overt or subclinical IGT and DM, with or 
without insulin resistance (IR)[18].
The negative influence of  SAGT on the survival of  
cirrhotic patients was demonstrated in one study car-
ried out in Japan, which found that patients with IGT or 
DM diagnosed by OGTT had a significantly lower 5-year 
survival rate[20]. However, similar findings have not been 
reported by others elsewhere.
The aims of  this study were: (1) to evaluate if  SAGT 
has any influence on survival of  patients with compen-
sated LC and normal FPG levels; and (2) to identify mor-
tality predictors.
designed for the study: gender, age, and family history of  
DM as well as laboratory blood test results (serum hemo-
globin, leukocytes, platelets, BUN, creatinine, albumin, 
bilirubin, aspartate aminotransferase, γ-glutamyltranspe
ptidase, alkaline phosphatase, cholesterol, triglycerides, 
and INR). The body mass index (BMI) was calculated 
and construed as follows: normal if  < 24.9, overweight if  
between 25 and 29.9, and obesity if  > 30[25]. Liver func-
tion was estimated using Child-Pugh and Model for End-
Stage Liver Disease (MELD) classifications[26,27].
Follow-up
All patients were followed every 3 mo in the outpatient 
department. A full clinical examination was made in each 
interview. Laboratory blood testing (serum hemoglobin, 
hematocrit, blood cell count, glucose, creatinine, BUN, 
liver function tests and coagulation tests) was also per-
formed. Moreover, plasma alpha-fetoprotein and liver ul-
trasonography were performed every 6 mo. Additionally, 
hospital admissions were recorded during which clinical 
course of  the patient was determined. Patients or their 
relatives were contacted by telephone when he or she did 
not attend to appointments. Callings were done in order 
to determine the clinical status of  the patient, or to in-
quire whether their death occurred. 
During follow-up patients were treated with life style 
and diet modifications, and in particular cases with oral 
hypoglycemic agents or insulin administration. No an-
tidiabetic medication was given to those with impaired 
glucose tolerance. 
Statistical analysis 
Continuous variables are expressed as means and stan-
dard deviations, while non-continuous variables as me-
dians and ranges. Categorical variables are expressed as 
relative proportions. Intergroup comparisons were made 
by Student’s t, χ 2 and Mann-Whitney tests. Variables were 
analyzed using the Cox proportional hazard regression 
model in order to determine independent predictive fac-
tors of  mortality[28]. Only the variables that were statisti-
cally significant in univariate analysis were analyzed in 
multivariate analysis. The results were expressed as HR 
with 95%CI, and the P value was calculated.
The cumulative survival was analyzed using the Ka-
plan-Meier method, and the curves were compared using 
log-rank test. A P value less than 0.05 was considered 
statistically significant. All statistical analyses were done 
using the statistical package SPSS v17.0 (Chicago, Illinois, 
United States).
RESULTS
Patient population
Of  293 cirrhotic patients evaluated, 124 (42.3%) met the 
inclusion criteria. However, 24 (8.1%) of  them were not 
finally included due to the following reasons: 13 refused 
to participate in the study, 8 found difficult to attend 
consultation because they lived in another state, and 3 
did not attend their appointments for performing OGTT 
(Figure 1).
Finally, 100 (34.1%) patients were included in the 
study. Their clinical and biochemical characteristics are 
shown in Table 1. Although BMI is not the best param-
eter for assessing nutritional status in cirrhotic patients 
(particularly in those with ascites), this method showed 
that most of  them (69%) were overweight or obese. The 
etiology of  cirrhosis was predominantly alcoholic and 
cryptogenic (47% and 26%, respectively). The diagnosis 
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Evaluated patients
with LC n  = 293
Fulfilled selection criteria 
n  = 124 (42.3%)
13 Refused to participate
8 Found difficult to attend 
consultations
3 Did not returned for OGTT
Included patients 
n  = 100 (34.1%)
OGTT
Normal 
n  = 30 (20.0%)
IGT 
n  = 44 (29.3%)
DM 
n  = 26 (17.3%)
Figure 1  Flowchart describing how selection of patients for the study was done. LC: Liver cirrhosis; OGTT: Oral glucose tolerance test; IGT: Impaired glucose 
tolerance; DM: Diabetes mellitus. 
García-Compeán D et al . Subclinical abnormal glucose tolerance and cirrhosis
times of  follow-up, oral antidiabetic medications were 
prescribed in 6, and subcutaneous insulin was prescribed 
in 2 out of  12 patients with overt DM.
In total, 49% of  alcoholic patients consistently 
stopped alcohol consumption, 47% of  patients with hep-
atitis C virus infection were treated with antiviral therapy, 
50% and 90% of  patients with hepatitis B virus infection 
or autoimmune liver disease were treated. There were no 
dropouts.
Cumulative survival
The mean survival time was 1448 d (range: 1256-1925) 
in the patients with NGT, while it was 1116 d (range 
990-1790) in the patients with SAGT (P = 0.045). Cumu-
lative survival curve of  patients with NGT and SAGT is 
shown in Figure 2. SAGT patients had significantly lower 
survival (P = 0.02).
One to 5-year survival rates are shown in Table 2. Sta-
tistically significant differences were observed only after 
three years of  follow-up. Increasing differences were ob-
served over time until the end of  follow-up.
Causes of death
In total 31 patients died (5 from the NGT group and 26 
from the SAGT group). The causes of  death are shown 
in Table 3. Twenty eight (90.3%) patients died due to the 
following complications related to liver disease: 8 due to 
esophageal variceal bleeding (25.8%), 6 due to chronic 
liver failure (19.3%), 5 due to spontaneous bacterial peri-
tonitis and other infections (16.2%), 5 due to hepatorenal 
syndrome (16.2%) and 4 due to hepatocellular carcinoma 
(12.9%). Additionally, 2 of  the remaining patients died 
due to renal impairment (6.4%), and 1 due to cardiovas-
of  LC was confirmed by liver biopsy in 44% of  cases. In 
total, 47% and 53% of  patients were assigned into the 
groups A and B of  the Child-Pugh classification, respec-
tively. The mean Child-Pugh score was 6.9 ± 1.8 points 
and the mean MELD score was 8.9 ± 4.8. The mean 
values of  FPI levels and HOMA2-IR index were 15.9 ± 
10.2 μU/mL and 2.67 ± 1.6, respectively. 
Clinical characteristics and survival rate of patients
Two groups were formed according to the results of  
OGTT: those with NGT (30 patients) and those with 
SAGT (70 patients, 44 with IGT and 26 with DM). Clini-
cal and biochemical characteristics are shown in Table 1. 
SAGT patients were significantly older and had higher val-
ues of  INR, FPI and HOMA2-IR. Although Child-Pugh 
and MELD scores were mildly higher in patients with 
SAGT, these differences were not statistically significant. 
Follow-up
The mean follow-up was 932 d (range 180-1925). At the 
end of  follow-up, 19 (19%) patients (5 NGT patients 
and 14 SAGT patients) developed overt IGT (7 cases) or 
overt DM (12 cases). All patients with SAGT were pre-
scribed dietary and life style modifications. At different 
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Table 1  Clinical and biochemical characteristics of cirrhotic 
patients
Variable Total (n  = 100) NGT (n  = 30) SAGT (n  = 70)
Age, yr 53.9 ± 11.8 49.0 ± 12.0    56.0 ± 11.11
BMI, kg/m2 26.9 ± 4.2 26.4 ± 4.40 27.21 ± 4.15
Males 60 (60) 18 (60) 42 (60)
Etiology: Alcohol 47 (47)    14 (46.6)    33 (47.1)
   HBV 4 (4)    1 (3.3)    3 (4.2) 
   HCV 13 (13)    2 (6.6)    11 (15.7)
   Autoimmunity 10 (10)   3 (10)   7 (10)
   Cryptogenic 26 (26)    10 (33.3)    16 (22.8)
Liver biopsy 44 (44)    13 (43.3)    31 (44.2)
Length of LC, mo   21.6 + 27.6 21.4 ± 30.6   21.7 ± 33.2
Hemoglobin, g/dL 11.8 ± 2.3      11.6 ± 2.1 11.9 ± 2.3
Platelets, × mm3 128140 ± 89501 159186 ± 112108 114834 ± 73269
INR   1.3 ± 0.3 1.2 ± 0.3  1.36 ± 0.32
Creatinine, mg/dL   0.8 ± 0.2 0.90 ± 0.33 0.83 ± 0.2
Albumin, g/dL     3.2 ± 0.73 3.33 ± 0.71   3.21 ± 0.74
ALT, UI/L   46.5 ± 40.8 48.9 ± 53.9   45.4 ± 34.0
Total bilirubin, 
mg/dL
  1.71 ± 0.90 1.55 ± 0.88   1.78 ± 0.91
Fasting plasma 
insulin, μU/mL
  15.9 ± 10.2      11.9 ± 7.6 18.2 ± 113
HOMA2 score 2.67 ± 1.6 2.36 ± 1.46    4.6 ± 3.34
Child-Pugh A 47 (47) 15 (50)    32 (45.7)
  B 53 (53) 15 (50)    38 (54.2)
Child Pugh score   6.8 ± 1.8   6.5 ± 1.61   6.82 ± 1.67
MELD score 8.94 ± 4.8 8.3 ± 5.2   9.21 ± 4.63
Survival, d 1237 1448 1116
(990-1925) (1256-1925) (990-1790)5
Data are expressed as absolute numbers (percentage) or mean ± SD. 1P 
= 0.003; 2P = 0.025; 3P = 0.03; 4P = 0.009; 5P = 0.045. NGT: Normal glucose 
tolerance; SAGT: Subclinical abnormal glucose tolerance; HOMA: Ho-
meostatic model assessment; LC: Liver cirrhosis. BMI: Body mass index; 
MELD: Model for End-Stage Liver Disease; HBV:  Hepatitis B virus; HCV: 
Hepatitis C virus; INR: International normalized ratio; ALT: Alanine trans-
aminase. 
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Figure 2  Cumulated survival of cirrhotic patients with normal glucose 
tolerance or subclinical abnormal glucose tolerance. Note that significant 
differences between both groups are evident after 3 years of follow-up. NGT: 
Normal glucose tolerance; SAGT: Subclinical abnormal glucose tolerance.
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cular disease (3.2%). There were no significant differ-
ences in the causes of  death among patients with NGT vs 
those with SAGT.
Predictors of death
Serum creatinine, albumin, INR, Child-Pugh B, Child-
Pugh and MELD scores, SAGT as well as FPI were 
statistically significant according to univariate analysis. 
However, only Child-Pugh B (HR = 8.2, 95%CI: 2.0-28.5, 
P = 0.02), Child-Pugh score (HR = 10.2, 95%CI: 2.4-21.9, 
P = 0.008), MELD score (HR = 12.3, 95%CI: 6.4-33.6, 
P = 0.001) and SAGT (HR = 3.2, 95%CI: 2.8-54.2, P = 
0.01) were independent predictors of  survival according 
to multivariate analysis (Table 4). 
DISCUSSION
Our study suggests that SAGT may have negative im-
pact on the survival of  patients with LC, as those who 
showed this abnormality had lower 5-year survival than 
those who had NGT. Significant differences in survival 
were observed after 3 years of  follow-up (Table 2). These 
results are consistent with another study carried out  in 
Japan, with 58 cirrhotic patients without overt DM who 
underwent OGTT[20]. In that study, 5-year survival rate 
was lower in patients with IGT and DM compared to 
those with NGT. Albumin and abnormal OGTT were 
independent negative predictors of  survival[20]. Despite 
the similarities in results of  both studies, ours differs in 
the following points: (1) 74% of  our patients had alco-
holic and cryptogenic cirrhosis, while 78.5% of  patients 
in the Japanese study had viral etiology (HBV and HCV). 
The causes of  chronic liver disease in our patients were 
identical to those observed in most Western countries, 
where alcohol and metabolic syndrome are the predomi-
nant causes (especially nowadays, the frequency of  obe-
sity and nonalcoholic fatty liver disease have dramatically 
increased), while viral etiology is predominantly observed 
in Asian countries[29-31]; (2) At time of  inclusion, our pa-
tients did not have liver-related complications, whereas 
in the Japanese study, up to 30% had ascites and hepatic 
encephalopathy; and (3) The number of  patients in our 
study was almost twice.
The mechanism by which SAGT may be involved in 
the occurrence of  death of  cirrhotic patients is difficult 
to explain. DM may induce progression of  liver fibrosis, 
inflammation and liver failure, or may increase cardiovas-
cular complications and atherosclerosis. In a study with 
virus C-infected patients, IR and DM were significantly 
associated with liver fibrosis[32]. Furthermore, in other 
reports, it has been suggested that DM can increase fibro-
sis, incidence of  hepatocellular carcinoma, and resistance 
to antiviral therapy in patients with hepatitis C[33]. DM 
may be involved in the progression of  liver fibrosis and 
inflammation through diverse mechanisms: it is likely that 
adipokine production (such as leptin and Tumor necrosis 
factor-alpha, which activate inflammatory pathways exac-
erbating liver injury) is increased by insulin resistance[34-36]. 
Leptin and oxidative stress associated with liver inflam-
mation may activate transforming growth factor beta 1 
(TGF-β1), which is one of  the most potent profibrogenic 
cytokines produced in the liver. TGF-β1 activates hepatic 
stellate cells which are the major source of  collagen Ⅰ and 
Ⅲ and extracellular matrix proteins[37-39]. In our study, 
SAGT as well as high Child-Pugh and MELD scores 
were independent predictors of  death. This suggests that 
SAGT combined with other etiologic agents of  liver cir-
rhosis might have induced liver failure and death. 
On the other hand, as it has been pointed out in other 
publications, most of  our patients with SAGT died from 
liver disease related complications[9,20,40] (Table 3). DM 
increases the incidence of  severe infections by inducing 
immunosuppression. Cirrhotic patients with DM have a 
higher prevalence of  infections compared to non-diabetic 
ones. In a recent study, spontaneous bacterial peritonitis 
was more frequent in patients with cryptogenic cirrhosis 
(which is associated with DM) compared to those with 
cirrhosis of  other causes[41]. These infected patients had 
higher in-hospital mortality due to sepsis, liver failure, and 
hepatorenal syndrome[42]. In addition, DM may increase 
the risk of  variceal bleeding, as postprandial hyperglyce-
mia that occurs in diabetic patients produces splanchnic 
vasodilatation and increases the flow and pressure of  the 
porto systemic venous system[43]. Also, esophageal vari-
ceal bleeding increases the risk of  infection and death by 
inducing bacterial intestinal translocation[44]. DM has been 
also associated with an increased risk of  hepatic encepha-
lopathy (HE). A significant association between malnutri-
tion and diabetes with HE was observed in a study with 
cirrhotic patients[45]. In multivariate analysis, Child-Pugh 
classification, malnutrition and DM showed independent 
correlations with HE. Plasma ammonium ion levels were 
related to insulin resistance and muscle mass. Authors 
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Table 2  Annual cumulated survival of cirrhotic patients  n  (%)
Year(s) NGT (n  = 30) SAGT (n  = 70) P  value (χ 2 test)
1 2 (93)   9 (87) 0.36
2   4 (83.2) 14 (79) 0.34
3   4 (83.2)    23 (51.4) 0.04
4   4 (83.2)    24 (47.5) 0.03
5   5 (71.6)    26 (31.7) 0.02
NGT: Normal glucose tolerance; SAGT: Subclinical abnormal glucose 
tolerance.
Table 3  Causes of death  n  (%)
Cause Total (n  = 31)
Variceal bleeding   8 (25.8)
Liver failure   6 (19.3)
SBP e infection   5 (16.2)
Hepatorenal syndrome   5 (16.2)
HCC   4 (12.9)
Renal impairment 2 (6.4)
Cardiovascular 1 (3.2)
 SBP: Spontaneous bacterial peritonitis; HCC: Hepatocellular carcinoma.
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concluded that nutritional status and insulin resistance 
might be implicated in the pathogenesis of  HE[45]. 
On the other hand, some authors reported low fre-
quency of  diabetic complications in cirrhotic patients[46]. 
However, these observations have been recently chal-
lenged: in two published studies, patients with chronic 
hepatitis C compared to controls, showed significant 
higher carotid intima media thickness, greater number of  
carotid plaques and carotid atherosclerosis affection[47,48]. 
In one of  these studies[47], older age and severe hepatic 
fibrosis were independently associated with early carotid 
atherosclerosis. In the other one[48], diabetes and meta-
bolic syndrome were associated with carotid plaques. The 
precise prevalence of  cardiovascular disease or athero-
sclerosis and their role in the induction of  death in cir-
rhotic patients with DM need to be defined in future well 
conducted studies. 
In our study, we did not observe significant differ-
ences in the causes of  death among patients with NGT 
compared to those with SAGT (Table 3). This may be 
due to the small number of  individuals in each group. 
Some differences might be clearly evident using a larger 
sample of  patients.
Although the negative impact of  DM on survival of  
cirrhotic patients is well known a long time ago, the ben-
eficial effects of  early detection and treatment of  DM 
and IGT for reducing complications and mortality rates 
have not been clearly determined. In our study, analysis 
of  this issue was not performed due to the low number 
of  patients. This important point has to be determined in 
future studies. 
In conclusion, SAGT disorders were associated with 
reduced long term survival in patients with compensated 
LC and normal FPG. Additionally, SAGT, Child-Pugh B, 
and high Child-Pugh and MELD scores were indepen-
dent negative predictors of  survival. These findings sug-
gest that SAGT may give rise to morbid conditions that 
increase mortality of  patients. According to this, OGTT 
is useful for accurate assessment of  mortality in non-
diabetic cirrhotic patients.
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Table 4  Univariate and multivariate analyses: Independent predictors of death
Variable HR 95%CI P  value HR 95%CI P  value
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SAGT 4.5 2.0-15.2 0.042   3.2 2.8-54.2 0.010
Fasting serum insulin 1.2 1.0-33.5 0.040   3.2 0.1-27.3 0.320
MELD: Model for end stage liver disease; INR: International normalized ratio; SAGT: Subclinical abnormal glucose tolerance.
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